Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective
Executive Summary
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
You may also be interested in...
FDA Expands Indication For Axonics’ Incontinence System; Medtronic Claims Patent Infringement
The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add seven new products, including Nulibry, BridgeBio/Sentynl's orphan drug for treating molybdenum cofactor deficiency Type A.
Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.